LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 146

Search options

  1. Article ; Online: Guest Editor's bio: Dr. Zuzana Diamant.

    Diamant, Zuzana

    Respiratory medicine

    2023  Volume 218, Page(s) 107400

    Language English
    Publishing date 2023-09-03
    Publishing country England
    Document type Editorial
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: An Update on Patient-Reported Outcomes in Asthma.

    Wu, Tianshi David / Diamant, Zuzana / Hanania, Nicola A

    Chest

    2024  

    Abstract: Topic importance: Patient-reported outcomes (PROs) are information provided by patients on their condition, function, well-being, or experience. Instruments to quantify PROs, called patient-reported outcome measures (PROMs), allow standardized ... ...

    Abstract Topic importance: Patient-reported outcomes (PROs) are information provided by patients on their condition, function, well-being, or experience. Instruments to quantify PROs, called patient-reported outcome measures (PROMs), allow standardized assessment of a unique dimension of health that cannot be measured physically. Herein, we discuss how to appraise PROMs critically and provide an update on their use in asthma clinical practice and research.
    Review findings: Asthma-specific PROMs have been developed to measure a wide array of disease characteristics, including symptoms, medication use, exacerbations, and impairments to emotional and physical function. Some PROMs also include spirometry or expand questions to overlap with rhinitis symptoms. Use of PROMs to understand asthma control is included in management guidelines, yet real-world evidence of their effectiveness in improving asthma care remains limited. These instruments may be less accurate in characterizing patients with poorly controlled asthma and have modest correlation with exacerbation risk. Two new PROMs are highlighted, the Asthma Impairment and Risk Questionnaire as an instrument to assess asthma control that incorporates domains related to exacerbation risk and impairment, and the CompEx as a composite of daily diary reporting combined with exacerbation events as an early efficacy signal for interventional trials.
    Summary: PROMs are fundamental to asthma assessment. Novel instruments may improve the detection of patients at risk for poor outcomes and shorten the drug discovery pipeline. However, urgent research is needed to understand their practical utility in clinical settings.
    Language English
    Publishing date 2024-02-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1016/j.chest.2024.02.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Integrating innovations in asthma research into clinical practice.

    Diamant, Zuzana / Seys, Sven F / Rogers, Linda / Hanania, Nicola A

    Respiratory medicine

    2023  Volume 217, Page(s) 107345

    MeSH term(s) Humans ; Asthma/therapy ; Biomedical Research
    Language English
    Publishing date 2023-07-14
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107345
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Editorial: Dealing with asthma during the turbulent times of coronavirus disease-2019.

    Diamant, Zuzana / Hanania, Nicola A

    Current opinion in pulmonary medicine

    2020  Volume 27, Issue 1, Page(s) 1–2

    Keywords covid19
    Language English
    Publishing date 2020-10-02
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1285505-4
    ISSN 1531-6971 ; 1070-5287 ; 1078-1641
    ISSN (online) 1531-6971
    ISSN 1070-5287 ; 1078-1641
    DOI 10.1097/MCP.0000000000000745
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Blood eosinophils: In quest of a Holy Grail for personalized asthma treatment with biologicals.

    Jesenak, Milos / Diamant, Zuzana

    Allergy

    2020  Volume 75, Issue 6, Page(s) 1294–1297

    MeSH term(s) Asthma/drug therapy ; Biological Products/therapeutic use ; Eosinophils ; Humans
    Chemical Substances Biological Products
    Language English
    Publishing date 2020-03-31
    Publishing country Denmark
    Document type Editorial
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.14253
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: An Algorithm for Strategic Continuation or Restriction of Asthma Medication Prior to Exercise Challenge Testing in Childhood Exercise Induced Bronchoconstriction.

    Hengeveld, Vera S / Keijzer, Pascal B / Diamant, Zuzana / Thio, Boony J

    Frontiers in pediatrics

    2022  Volume 10, Page(s) 800193

    Abstract: Exercise induced bronchial (EIB) constriction is a common and highly specific feature of pediatric asthma and should be diagnosed with an exercise challenge test (ECT). The impact of EIB in asthmatic children's daily lives is immense, considering the ... ...

    Abstract Exercise induced bronchial (EIB) constriction is a common and highly specific feature of pediatric asthma and should be diagnosed with an exercise challenge test (ECT). The impact of EIB in asthmatic children's daily lives is immense, considering the effects on both physical and psychosocial development. Monitoring childhood asthma by ECT's can provide insight into daily life disease burden and the control of asthma. Current guidelines for bronchoprovocation tests restrict both the use of reliever and maintenance asthma medication before an exercise challenge to prevent false-negative testing, as both have significant acute bronchoprotective properties. However, restricting maintenance medication before an ECT may be less appropiate to evaluate EIB symptoms in daily life when a diagnosis of asthma is well established. Rigorous of maintenance medication before an ECT according to guidelines may lead to overestimation of the real, daily life asthma burden and lead to an inappropiate step-up in therapy. The protection against EIB offered by the combined acute and chronic bronchoprotective effects of maintenance medication can be properly assessed whilst maintaining them. This may aid in achieving the goal of unrestricted participation of children in daily play and sports activities with their peers without escalation of therapy. When considering a step down in medication, a strategic wash-out of maintenance medication before an ECT aids in providing objective support of potential discontinuation of maintenance medication.
    Language English
    Publishing date 2022-02-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2711999-3
    ISSN 2296-2360
    ISSN 2296-2360
    DOI 10.3389/fped.2022.800193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Asthma in the era of COVID-19.

    Assaf, Sara / Stenberg, Henning / Jesenak, Milos / Tarasevych, Svitlana P / Hanania, Nicola A / Diamant, Zuzana

    Respiratory medicine

    2023  Volume 218, Page(s) 107373

    Abstract: Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/ ... ...

    Abstract Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.
    MeSH term(s) Humans ; COVID-19/epidemiology ; COVID-19/complications ; SARS-CoV-2 ; Asthma/diagnosis ; Comorbidity ; Adrenal Cortex Hormones/therapeutic use
    Chemical Substances Adrenal Cortex Hormones
    Language English
    Publishing date 2023-08-10
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107373
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Allergen immunotherapy for allergic asthma: The future seems bright.

    Diamant, Zuzana / van Maaren, Maurits / Muraro, Antonella / Jesenak, Milos / Striz, Ilja

    Respiratory medicine

    2023  Volume 210, Page(s) 107125

    Abstract: Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset ... ...

    Abstract Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.
    MeSH term(s) Animals ; Humans ; Asthma/etiology ; Desensitization, Immunologic ; Rhinitis, Allergic/drug therapy ; Allergens ; Pollen ; Antigens, Dermatophagoides/therapeutic use ; Pyroglyphidae ; Sublingual Immunotherapy
    Chemical Substances Allergens ; Antigens, Dermatophagoides
    Language English
    Publishing date 2023-01-24
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.

    Rogers, Linda / Jesenak, Milos / Bjermer, Leif / Hanania, Nicola A / Seys, Sven F / Diamant, Zuzana

    Respiratory medicine

    2023  Volume 218, Page(s) 107414

    Abstract: The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of ...

    Abstract The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which treatments have been demonstrated to be steroid sparing in corticosteroid dependent asthma, and provide practical guidance that can drive shared decision making on treatment choice with patients. In addition, we summarize what is known to date regarding long-term safety of these drugs, and lastly, discuss future directions in biologics research.
    MeSH term(s) Adult ; Child ; Humans ; Biological Products/therapeutic use ; Asthma ; Biomarkers ; Phenotype ; Precision Medicine ; Anti-Asthmatic Agents/therapeutic use
    Chemical Substances Biological Products ; Biomarkers ; Anti-Asthmatic Agents
    Language English
    Publishing date 2023-09-29
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Clinical and daily respiratory care and clinical trials within the COVID-19 era.

    Diamant, Zuzana / Backer, Vibeke / Bjermer, Leif

    European clinical respiratory journal

    2020  Volume 7, Issue 1, Page(s) 1766817

    Keywords covid19
    Language English
    Publishing date 2020-05-25
    Publishing country United States
    Document type Editorial
    ZDB-ID 2834928-3
    ISSN 2001-8525
    ISSN 2001-8525
    DOI 10.1080/20018525.2020.1766817
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top